SCHEMBL2138906

SCHEMBL2138906

CN(C)C1(Cc2ccccc2)CCC2(CC1)c1[nH]c3ccccc3c1CCN2C(=O)/C=C/c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.54
OGFRL1 Q5TC84 3/20 0.54
OPRL1 P41146 2/20 0.46
HDAC1 Q13547 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
PDE5A O76074 1/20 0.38
KMT2A Q03164 3/20 0.36
TRPA1 O75762 2/20 0.36
TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2138913 1.00 OPRM1 (0.54) OPRM1OGFRL1OPRL1HDAC1HDAC6
SCHEMBL3570168 0.88 OPRM1 (0.52) OPRM1OGFRL1OPRL1HDAC1HDAC6
SCHEMBL3570170 0.88 OPRM1 (0.52) OPRM1OGFRL1OPRL1HDAC1HDAC6
SCHEMBL2140335 0.87 OPRM1 (0.58) OPRM1OGFRL1OPRL1HDAC6KMT2A
SCHEMBL517328 0.85 OPRM1 (0.75) OPRM1OGFRL1OPRL1OPRD1
SCHEMBL10038870 0.85 OPRM1 (0.75) OPRM1OGFRL1OPRL1OPRD1
SCHEMBL517329 0.85 OPRM1 (0.75) OPRM1OGFRL1OPRL1OPRD1
SCHEMBL19535595 0.83 OPRM1 (0.66) OPRM1OGFRL1OPRL1HDAC1HDAC6
SCHEMBL2140032 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1KMT2ATRPA1
SCHEMBL2139574 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US claimed
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2016-09-22 US disclosed
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2016-09-22 US disclosed
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2014-10-09 US disclosed
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2014-10-09 US disclosed
EP-1868600-B1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY GRUENENTHAL GMBH (DE) 2012-06-27 EP disclosed
US-8034936-B2 Spirocyclic cyclohexane compounds useful to treat substance dependency GRUENENTHAL GMBH (DE) 2011-10-11 US disclosed
US-8034936-B2 Spirocyclic cyclohexane compounds useful to treat substance dependency GRUENENTHAL GMBH (DE) 2011-10-11 US disclosed
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2011-03-03 US disclosed
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2011-03-03 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor OPRM1, OPRK1, OPRD1 OPRM1 1/4885OGFRL1 34/4885OPRL1 4/4885
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.